The US Food and Drug Administration (FDA) has granted approval to Switzerland-based Roche for its Rozlytrek (entrectinib) intended for the treatment of adults with ROS1-positive and metastatic non-small cell lung cancer (NSCLC), it was reported on Friday.
The firm has also received accelerated approval for the product to treat adult and paediatric patients 12 years of age and older with solid tumours, which have a neurotrophic tyrosine receptor kinase gene fusion without a known acquired resistance mutation.
Rozlytrek is an oral medicine and selective tyrosine kinase inhibitor developed to inhibit the kinase activity of the TRK A/B/C and ROS1 proteins. It holds capacity to inhibit ROS1 and NTRK kinase activity and is likely to result in the death of cancer cells with ROS1 or NTRK gene fusions. The product has received approvals based on data from the integrated analysis of the pivotal phase II STARTRK-2, phase I STARTRK-1 and phase I ALKA-372-001 trials, and data from the phase I/II STARTRK-NG study.
Roche has claimed that Rozlytrek shrank tumours in 78 percent of people with the disease and the duration of response (DoR) ranged from 1.8 to 36.8+ months in ROS1-positive and metastatic NSCLC.
Amneal announces launch of PEMRYDI RTU, a ready-to-use oncology injectable
Medivir and Vetbiolix report positive results from VBX-1000 Proof-of-Concept clinical study
Norgine submits first marketing authorisation application submissions for approval of eflornithine
Innovent Biologics names new Oncology CMO
UroGen's UGN-103 IND accepted by FDA for bladder cancer treatment
Innate Pharma advances Sanofi-developed NK cell engager to Phase 2 for blood cancer patients
Precision Epigenomics partners with TruDiagnostic
Portage Biotech expands evaluation of strategic alternatives
Stamford Pharmaceuticals starts locally advanced basal cell carcinoma (laBCC) trial of SP-002
Candel Therapeutics granted FDA Orphan Drug Designation for CAN-2409 in pancreatic cancer treatment
ELIAS Animal Health names new chief revenue officer
Innate Pharma reports preclinical efficacy of IPH45
Roche attains CE Mark for first companion diagnostic for HER2-low metastatic breast cancer
BioCity Biopharma's BC2027 Phase one study IND application receives US FDA approval